---
title: "Expert Review and Recommendations on EGPA Diagnosis and Management"
id: "frontiers-in-immunology-1-expert-review-and-recommendations-on-the-diagnosis-and-therapeutic-management-of-eosinophilic-granulomatosis-with-polyangiitis"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-expert-review-and-recommendations-on-the-diagnosis-and-therapeutic-management-of-eosinophilic-granulomatosis-with-polyangiitis"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1785849"
published_at: "2026-04-13T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Expert Review and Recommendations on EGPA Diagnosis and Management
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-expert-review-and-recommendations-on-the-diagnosis-and-therapeutic-management-of-eosinophilic-granulomatosis-with-polyangiitis
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1785849)
- **Published At:** 2026-04-13T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and heterogeneous immune-mediated disorder in which eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. In clinical practice, diagnosis remains challenging because no single biomarker reliably captures disease complexity, and therapeutic decisions must still be based on careful integration of clinical, laboratory, imaging, and histopathological findings. In recent years, EGPA management has evolved from a largely glucocorticoid-based approach toward a more phenotype-oriented strategy that distinguishes eosinophilic and vasculitic manifestations and incorporates targeted biologic therapies. This Perspective discusses current challenges and emerging opportunities in EGPA diagnosis and treatment, with emphasis on early recognition, multidisciplinary assessment, glucocorticoid-sparing strategies, and individualized long-term follow-up. Specific recommendations are provided on diagnostic orientation, phenotype-driven therapeutic selection, and the practical use of conventional immunosuppressants and anti–IL-5/IL-5R biologics according to disease severity and organ involvement. In addition, we propose a new treatment algorithm intended to support real-world decision-making and to facilitate a more consistent and structured approach to care.
## Clinical Analysis & Structured Key Points
Diagnostic and therapeutic landscape of EGPA: expert synthesis Context and scope: - Eosinophilic granulomatosis with polyangiitis (EGPA) is described as a rare, heterogeneous immune-mediated disorder characterized by overlapping eosinophilic inflammation, vasculitis, and airway disease. - Diagnosis remains challenging due to the absence of a single reliable biomarker; clinical, laboratory, imaging, and histopathological data must be integrated for decision-making. Study design and perspective: - The content presents expert perspectives and recommendations rather than new primary trial data. - Emphasis is placed on diagnosis, multidisciplinary assessment, and long-term, phenotype-driven management. Key themes and recommendations: - Phenotype-driven strategy: management increasingly distinguishes eosinophilic from vasculitic manifestations to guide therapy. - Glucocorticoid-sparing approaches: a shift away from solely glucocorticoid-based treatment toward tailored regimens aiming to minimize steroid exposure. - Targeted biologics: incorporation of anti–IL-5/IL-5R therapies alongside conventional immunosuppressants, selected according to disease severity and organ involvement. - Practical guidance: diagnostic orientation, therapeutic selection aligned with phenotype, and structured use of conventional immunosuppressants and biologics in real-world settings. - Algorithmic framework: proposal of a new treatment algorithm to support consistent, decision-ready care pathways. Limitations and uncertainties: - The article acknowledges ongoing challenges in early recognition and the need for multidisciplinary, individualized long-term follow-up. - It notes the evolving therapeutic landscape and the necessity for safer, more effective, and personalized treatment strategies, without presenting new quantitative outcomes.
## Related Clinical Research

- [Pharmacokinetic variability of baloxavir marboxil among 14 rare avian species](https://medichelpline.com/clinical-feed/plos-one-16-pharmacokinetic-diversity-of-baloxavir-marboxil-across-rare-avian-species.md)
- [Viral meningitis in Ethiopia: enteroviruses dominate clinical cases and outcomes](https://medichelpline.com/clinical-feed/plos-one-7-the-hidden-burden-of-viral-meningitis-in-ethiopia-etiology-and-clinical-outcomes.md)
- [WHO releases working papers on training and practice in traditional medicine](https://medichelpline.com/clinical-feed/who-0-0-who-launches-working-papers-on-traditional-medicine.md)
- [Global Diagnostics Coalition urges coordinated action to close global diagnostic gap](https://medichelpline.com/clinical-feed/who-0-2-global-diagnostics-coalition-calls-for-collective-action-to-close-the.md)
- [C1q interaction enhances monoclonal antibody protection against lethal HSV-1 in neonatal mice](https://medichelpline.com/clinical-feed/biorxiv-4-interaction-with-complement-factor-c1q-can-contribute-to-and-improve-monoclonal.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.